
United States
Securities and Exchange Commission
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934

September 14, 2010
(Date of Report)

ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation)

000-20852
(Commission File Number)

16-1387013
(IRS Employer Identification No.)

2000 Technology Parkway, Newark, New York
(Address of principal executive offices)

14513
(Zip Code)

(315) 332-7100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Item 8.01. Other Events.

Ultralife has received an Indefinite Quantity Contract to source its BA 5390 batteries to the Defense Logistics Agency (DLA).

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed to be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated September 17, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 17, 2010

ULTRALIFE CORPORATION

/s/ Peter F. Comerford

Peter F. Comerford

Vice President of Administration and General Counsel

Ultralife Corporation Receives Award for its BA 5390 Military Batteries from Defense Logistics Agency

NEWARK, N.Y.--(BUSINESS WIRE)--September 17, 2010--Ultralife Corporation (NASDAQ: ULBI) has received an Indefinite Quantity Contract to source its BA 5390 batteries to the Defense Logistics Agency (DLA). The award consists of one base year, commencing on September 14, 2010, with four option years to be exercised in one-year increments at the discretion of the Government. DLA has estimated annual demand value for the base year at \$5.3 million and has estimated the total award not to exceed \$42.1 million.

“We are pleased to continue our partnership as the chosen supplier of our BA 5390 batteries to the US military. This award demonstrates the recognized quality of our products in mission critical applications. The BA 5390 is recognized for its long life, unsurpassed safety record and ability to lighten the load for the warfighter,” said John D. Kavazanjian, president and chief executive officer.

About Ultralife Corporation

Ultralife Corporation, which began as a battery company, serves its markets with products and services ranging from portable and standby power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the company’s business segments include: Battery & Energy Products, Communications Systems and Energy Services. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorp.com.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: worsening global economic conditions, increased competitive environment and pricing pressures, and the possibility of intangible asset impairment charges that may be taken should management decide to retire one or more of the brands of acquired companies. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company’s analysis only as of today’s date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

CONTACT:

[Ultralife Corporation](#)

Philip Fain, 315-332-7100

pfain@ulbi.com

or

Investor Relations:

[Lippert/Heilshorn & Associates, Inc.](#)

Jody Burfening, 212-838-3777

jburfening@lhai.com